Case-Based Roundtable®

This roundtable series explores biomarker testing and targeted therapy for patients with grade 2 astrocytoma or oligodendroglioma with IDH1 or IDH 2 mutations, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series examines therapy for patients with metastatic small cell lung cancer after first-line therapy, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series considers treatments for maintenance after first-line chemotherapy in patients with locally advanced or metastatic bladder cancer, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series explores immune checkpoint inhibitors and combination therapy for patients with unresectable or metastatic hepatocellular carcinoma in the frontline setting, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series looks at previously-treated patients with unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series assesses treatment for patients with extensive-stage small cell lung cancer that reduce adverse events after prior therapy, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series examines options for patients with metastatic pancreatic adenocarcinoma such as chemotherapy in those who had not received chemotherapy prior, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series discusses second-line options in patients with B-cell lymphoma, including CAR T-cell therapy, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series reviews treatment after progression for patients with advanced melanoma, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series considers testing for patients with HER2-negative, early-stage breast cancer, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series explores options regardless of past treatments in adult patients with polycythemia vera, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series looks at therapies available in patients with later-line metastatic colorectal cancer, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series assesses immunotherapy plus chemotherapy as treatment for metastatic or recurrent nasopharyngeal carcinoma, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series examines systemic treatment in patients with desmoid tumors which have progressed, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series discusses the option of testing circulating tumor DNA molecular residual disease for personalized care in patients with lung cancer, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series explores therapies available for patients with differentiated thyroid cancer after they have radioactive iodine-refractory disease, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series looks at combination treatments in the unresectable or metastatic bladder cancer population, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series considers antibody-drug conjugate and other therapies for patients with HER2-positive breast cancer, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series assesses chimeric antigen receptor T-cell therapy as later-line treatment in patients with relapsed/refractory multiple myeloma, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series discusses the use of therapy after or instead of erythropoiesis-stimulating agents in patients with low- to intermediate-1 risk myelodysplastic syndromes, as discussed by key opinion leaders at virtual live events and interviews.

This roundtable series examines combination therapy for treatment-naive patients with unresectable or metastatic hepatocellular carcinoma, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series looks at the use of CAR T-cell therapy for patients with large B-cell lymphoma and how this is expanding treatment options for these patients in the second-line setting, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series reviews the treatment of patients with advanced ALK-positive non–small cell lung cancer, as discussed by key opinion leaders and participants at virtual live events.

In this roundtable series, expert physicians look at the use of luspatercept-amt to treat anemia in patients with myelodysplastic syndromes throughout the course of treatment.

This roundtable series looks at therapies available for patients with colorectal cancer after prior lines of treatment, as discussed by key opinion leaders and participants at virtual live events.

This Evolving Paradigm Roundtable reviews the later-line options for patients with hormone receptor–positive, HER2-low or -negative inoperable or metastatic breast cancer, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series assesses the use of immunotherapies in combination for patients with renal cell carcinoma, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series examines therapeutic options for patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series considers the operationalization of care for patients with relapsed/refractory multiple myeloma, as discussed by key opinion leaders and participants at virtual live events.